The long-term goals of this project are to understand the molecular basis for a group of closely related congenital myopathies and muscular dystrophies, and to use this information to develop therapies for patients with these debilitating conditions. X-linked myotubular myopathy (XLMTM) is caused by mutations of the MTM1 gene, which encodes myotubularin, an enzyme lipid phosphatase important for biogenesis and function of T tubules, which are the structures in skeletal muscles responsible for transmitting the signal to contract to the contractile apparatus. The centronuclear myopathies (CNMs), of which XLMTM is a subtype, also include forms caused by mutations in the RYR1, DNM2, and BIN1 genes, which are all known or thought to play a role in excitation contraction coupling (ECC) at the triads. Some families with CNM have mutations in genes that have yet to be identified.
The specific aims of this proposal are 1) to conduct studies designed to evaluate the potential for myostatin-inhibition therapy in a mouse model of XLMTM and 2) to complete the identification of the various genes that cause human CNMs and related myopathies. Each of the genes shown to cause a form of human CNM will then 3) be modeled in existing or new targeted zebrafish mutants, and 4) these lines will be characterized and developed for use in high throughput drug screens to identify lead compounds with therapeutic potential for these and related disorders of ECC in patients with primary myopathies and muscular dystrophies. The successful conclusion of these studies will result in development of accurate genetic tests to diagnose these conditions in affected children and family members, allowing for reliable family planning to avoid the birth of additional affected children. Furthermore, the identification of new drugs and small molecules that slow or prevent the development of weakness in the mouse and zebrafish models used in this study will set the stage for preclinical testing of new therapies that may one day be used to treat children with these devastating neuromuscular diseases.
Neuromuscular diseases, such as the centronuclear myopathies that are the focus of this proposal, lead to severe skeletal muscle weakness, inability to walk, difficulty in conduct of daily activities, and premature death, often in infancyor early childhood. Genes and therapies for centronuclear myopathies is highly relevant to public health because it will result in identification of the remaining genes responsible for these conditions, allowing for accurate diagnosis, early detection of disease, and prenatal diagnosis to help families ensure the birth of healthy children. In addition, through the use of innovative mouse and zebrafish models, new drugs and therapies will be identified and tested, leading to development of future treatments for children and adults born with these crippling diseases.
|Sarwal, Aarti; Cartwright, Michael S; Walker, Francis O et al. (2014) Ultrasound assessment of the diaphragm: Preliminary study of a canine model of X-linked myotubular myopathy. Muscle Nerve 50:607-9|
|Marttila, Minttu; Lehtokari, Vilma-Lotta; Marston, Steven et al. (2014) Mutation update and genotype-phenotype correlations of novel and previously described mutations in TPM2 and TPM3 causing congenital myopathies. Hum Mutat 35:779-90|
|Agrawal, Pankaj B; Joshi, Mugdha; Marinakis, Nicholas S et al. (2014) Expanding the phenotype associated with the NEFL mutation: neuromuscular disease in a family with overlapping myopathic and neurogenic findings. JAMA Neurol 71:1413-20|
|Agrawal, Pankaj B; Pierson, Christopher R; Joshi, Mugdha et al. (2014) SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy. Am J Hum Genet 95:218-26|
|Smith, Laura L; Gupta, Vandana A; Beggs, Alan H (2014) Bridging integrator 1 (Bin1) deficiency in zebrafish results in centronuclear myopathy. Hum Mol Genet 23:3566-78|
|Lawlor, Michael W; Viola, Marissa G; Meng, Hui et al. (2014) Differential muscle hypertrophy is associated with satellite cell numbers and Akt pathway activation following activin type IIB receptor inhibition in Mtm1 p.R69C mice. Am J Pathol 184:1831-42|
|Goddard, Melissa A; Burlingame, Emily; Beggs, Alan H et al. (2014) Gait characteristics in a canine model of X-linked myotubular myopathy. J Neurol Sci 346:221-6|
|Lamont, Phillipa J; Wallefeld, William; Hilton-Jones, David et al. (2014) Novel mutations widen the phenotypic spectrum of slow skeletal/?-cardiac myosin (MYH7) distal myopathy. Hum Mutat 35:868-79|
|Childers, Martin K; Joubert, Romain; Poulard, Karine et al. (2014) Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med 6:220ra10|
|Yuen, Michaela; Sandaradura, Sarah A; Dowling, James J et al. (2014) Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy. J Clin Invest 124:4693-708|
Showing the most recent 10 out of 83 publications